Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Performance status (PS), a subjective measure of the functional status of a patient with cancer and his or her ability to perform normal activities, is influenced both by tumor-related and by comorbidity-related factors. It is a reliable independent prognostic indicator for survival in patients with advanced non-small cell lung cancer. Patients with a poor PS (PS2) constitute up to 30% to 40% of the population of patients with advanced non-small cell lung cancer, yet they are underrepresented in clinical trials. These patients are heterogeneous, which makes it challenging to use their PS scores alone to guide their therapy. A greater understanding of PS scores and the factors that affect them can be gained through PS2-specific clinical trials, which can lead to the development of better PS instruments to aid in making therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 11
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Clinical Trials
Aptitude
Comorbidity
Neoplasms
Decision Making
Survival
Therapeutics
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. / Kelly, Karen.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 11, 12.2004, p. 3-7.

Research output: Contribution to journalArticle

@article{5d9180fbacd44b5c9df91e8609392ac8,
title = "Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status",
abstract = "Performance status (PS), a subjective measure of the functional status of a patient with cancer and his or her ability to perform normal activities, is influenced both by tumor-related and by comorbidity-related factors. It is a reliable independent prognostic indicator for survival in patients with advanced non-small cell lung cancer. Patients with a poor PS (PS2) constitute up to 30{\%} to 40{\%} of the population of patients with advanced non-small cell lung cancer, yet they are underrepresented in clinical trials. These patients are heterogeneous, which makes it challenging to use their PS scores alone to guide their therapy. A greater understanding of PS scores and the factors that affect them can be gained through PS2-specific clinical trials, which can lead to the development of better PS instruments to aid in making therapeutic decisions.",
author = "Karen Kelly",
year = "2004",
month = "12",
doi = "10.1053/j.seminoncol.2004.10.003",
language = "English (US)",
volume = "31",
pages = "3--7",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 11",

}

TY - JOUR

T1 - Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status

AU - Kelly, Karen

PY - 2004/12

Y1 - 2004/12

N2 - Performance status (PS), a subjective measure of the functional status of a patient with cancer and his or her ability to perform normal activities, is influenced both by tumor-related and by comorbidity-related factors. It is a reliable independent prognostic indicator for survival in patients with advanced non-small cell lung cancer. Patients with a poor PS (PS2) constitute up to 30% to 40% of the population of patients with advanced non-small cell lung cancer, yet they are underrepresented in clinical trials. These patients are heterogeneous, which makes it challenging to use their PS scores alone to guide their therapy. A greater understanding of PS scores and the factors that affect them can be gained through PS2-specific clinical trials, which can lead to the development of better PS instruments to aid in making therapeutic decisions.

AB - Performance status (PS), a subjective measure of the functional status of a patient with cancer and his or her ability to perform normal activities, is influenced both by tumor-related and by comorbidity-related factors. It is a reliable independent prognostic indicator for survival in patients with advanced non-small cell lung cancer. Patients with a poor PS (PS2) constitute up to 30% to 40% of the population of patients with advanced non-small cell lung cancer, yet they are underrepresented in clinical trials. These patients are heterogeneous, which makes it challenging to use their PS scores alone to guide their therapy. A greater understanding of PS scores and the factors that affect them can be gained through PS2-specific clinical trials, which can lead to the development of better PS instruments to aid in making therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=10044225886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044225886&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.10.003

DO - 10.1053/j.seminoncol.2004.10.003

M3 - Article

C2 - 15599828

AN - SCOPUS:10044225886

VL - 31

SP - 3

EP - 7

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 11

ER -